Janssen, the pharmaceutical division of the Johnson & Johnson companies, announced Wednesday that it will scrap development of a vaccine for respiratory syncytial virus, or RSV, in adults.
from CNN.com - RSS Channel - HP Hero https://ift.tt/bdLkDlV
Wednesday, 29 March 2023
Johnson & Johnson halts development of RSV vaccine in midst of late-stage clinical trials
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment